NBE-Therapeutics has obtained a second granted US patent covering certain compositions for NBE's ADCs conjugated to highly potent anthracycline payloads
NBE-Therapeutics today announces that the Unites States Patent and Trademark Office (US-PTO) has granted a second US patent to NBE-Therapeutics covering certain compositions of NBE's highly potent anthracycline toxin payload, which NBE-Therapeutics is using to develop next-generation immune-stimulatory antibody drug conjugates (iADCs). The granted patent is entitled "Binding protein drug conjugates comprising anthracycline derivatives" and is accessible and published under the US patent number: US 10,517,959 B2.
Together with the already granted US patent 10,188,745 B2 covering methods of prduction and ADCs conjugated to NBE's highly potent anthracycline toxin payload and with granted US patent US 9,872,923 B2 relating to NBE-Therapeutics' sortase-enzyme mediated antibody conjugation technology (SMAC-technology), NBE Thwerapeutics now owns three key patents related to the development of site-specifically conjugated iADCs with highly potent anthracycline payloads.